{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-24-002423","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.167365+00:00","generated_at":"2026-06-06T01:00:42.304910+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Tonix shareholders approve issuance of up to 162M shares upon warrant exercise","bullets":["Shareholders approved up to 162,162,162 shares issuable upon exercise of Series C and D warrants.","Vote: 7,560,035 for, 1,453,119 against, 57,620 abstentions.","9,070,774 shares (33.9% of outstanding) represented at Feb 15, 2024 special meeting.","Adjournment proposal also approved: 7,553,051 for, 1,388,810 against.","Warrants issued in Dec 22, 2023 offering; approval needed for Nasdaq Listing Rule 5635(d)."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-24-002423","json":"https://secwatch.observer/filing/0001999371-24-002423.json","markdown":"https://secwatch.observer/filing/0001999371-24-002423.md","text":"https://secwatch.observer/filing/0001999371-24-002423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124002423/0001999371-24-002423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124002423/tnxp-8k_021524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:00:42.304910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9464b920f3e79ff45c1021f114d89e864f702b0a","claim":"Tonix Pharmaceuticals Holding Corp. shareholders approved Approval of issuance of shares upon exercise of Series C and Series D warrants for Nasdaq compliance at the 2024-02-15 meeting.","evidence_excerpt":"The Company’s shareholders approved, for the purpose of complying with the applicable provisions of The Nasdaq Stock Market LLC Listing Rule 5635(d), the issuance of up to 162,162,162 shares of the Company’s common stock issuable upon the exercise of the Company’s outstanding Series C warrants and Series D warrants issued to institutional investors in connection with an offering by the Company that closed on December 22, 2023, as set forth below: Votes For Votes Against Abstentions Broker Non-Votes 7,560,035 1,453,119 57,620 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124002423/0001999371-24-002423-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-02-15"}],"fact_type":"shareholder_vote"},{"claim_id":"a73882698f084d9a77bf9661fb8b21eef2921185","claim":"Tonix Pharmaceuticals Holding Corp. shareholders approved Approval of adjournment of Special Meeting if necessary to solicit additional proxies at the 2024-02-15 meeting.","evidence_excerpt":"The Company’s shareholders approved a proposal for the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve Proposal 1, as set forth below: Votes For Votes Against Abstentions Broker Non-Votes 7,553,051 1,388,810 128,067 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124002423/0001999371-24-002423-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-02-15"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}